Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CVD001
MIFTS: 57

Covid-19

Categories: Infectious diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Covid-19

About this section

MalaCards integrated aliases for Covid-19:

Name: Covid-19 12 29 42 15
Wuhan Seafood Market Pneumonia Virus Infection 12
Wuhan Coronavirus Infection 12
2019 Novel Coronavirus 12
Sars-Cov-2 Infection 12
2019-Ncov Infection 12
Covid19 12

Classifications:

MalaCards categories:
Global: Infectious diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:0080600
NCIt 50 C171133
UMLS 71 C5203670
Sources

Summaries for Covid-19

About this section
MedlinePlus : 42 COVID-19 (coronavirus disease 2019) is an illness caused by a virus. This virus is a new coronavirus that has spread throughout the world. It is thought to spread mainly through close contact from person to person. On this page, you'll find links to resources on important issues such as symptoms, risks, and how you can protect yourself and your family. We also have pages on COVID-19 testing and vaccines, including the vaccines that have been authorized in the United States and the others that are still in progress.

MalaCards based summary : Covid-19, also known as wuhan seafood market pneumonia virus infection, is related to adult respiratory distress syndrome and disease by infectious agent. An important gene associated with Covid-19 is ACE2 (Angiotensin Converting Enzyme 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ledipasvir and Bentonite have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are cardiovascular system and hematopoietic system

Disease Ontology : 12 A Coronavirus infection that is characterized by fever, cough and shortness of breath and that has material basis in SARS-CoV-2.

Sources

Related Diseases for Covid-19

About this section

Diseases related to Covid-19 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1847)
# Related Disease Score Top Affiliating Genes
1 adult respiratory distress syndrome 32.1 IL6 IL1B IFNA2 CXCL8 ACE
2 disease by infectious agent 32.0 TLR4 IL6 IL4 IL1B IFNB1
3 middle east respiratory syndrome 32.0 TMPRSS2 IFNB1 DPP4 CXCL10 ACE2
4 pulmonary embolism 31.9 TNNI3 NPPB F3 ACE
5 severe acute respiratory syndrome 31.7 TMPRSS2 TLR4 IL6 IL1B IFNB1 CXCL8
6 cardiogenic shock 31.7 NPPB IL6
7 pneumonia 31.6 TLR4 IL6 IL4 IL1B CXCL8 CXCL10
8 stroke, ischemic 31.6 TLR4 NPPB IL6 IL1B F3 ACE
9 influenza 31.6 TMPRSS2 IL6 IL1B IFNB1 CXCL10
10 cerebrovascular disease 31.5 TLR4 NPPB IL6 ACE
11 congestive heart failure 31.5 TNNI3 NPPB IL6 IL1B ACE
12 viral pneumonia 31.4 IL6 IFNB1 CXCL8 CXCL10 ACE2
13 kawasaki disease 31.4 NPPB IL6 IL4 IL1B CCL2
14 hemopericardium 31.4 TNNI3 F3
15 conjunctivitis 31.4 IL6 IL4 CXCL8 CCL2
16 mycobacterium tuberculosis 1 31.3 TLR4 IL4 IFNB1 CXCL10
17 respiratory failure 31.3 TLR4 NPPB IL6 IL1B F3 CXCL8
18 acute myocarditis 31.3 TNNI3 NPPB ACE
19 mental depression 31.3 IL6 IL1B DPP4
20 plague 31.3 TLR4 IL6 IL1B
21 back pain 31.3 IL6 IL1B
22 bacterial pneumonia 31.2 TLR4 IL6 IL1B CXCL8
23 encephalitis 31.2 IL6 IL1B IFNB1 CXCL10 CCL2
24 dermatitis 31.2 IL6 IL4 IL1B CXCL8
25 limb ischemia 31.2 TNNI3 IL6 CCL2 ACE
26 sleep disorder 31.2 IL6 IL1B CXCL8 ACE
27 chickenpox 31.2 IL6 IL4 IFNB1
28 myocarditis 31.2 TNNI3 TLR4 NPPB IL6 IL4 IL1B
29 myelitis 31.2 IL6 IFNB1 CXCL8
30 pericardial effusion 31.2 TNNI3 NPPB IL6 F3 ACE
31 measles 31.1 TLR4 IL6 IL2RA IL1B IFNB1
32 purpura 31.1 IL6 IL4 IL1B F3 ACE
33 orchitis 31.1 IL6 IL1B ACE2
34 acute pancreatitis 31.1 TLR4 IL6 IL1B CXCL8
35 exanthem 31.1 IL6 IL1B F3 EGFR CXCL8 ACE
36 appendicitis 31.1 TLR4 IL6 IL1B CXCL8 CCL2
37 erythema multiforme 31.1 IL6 IL4 CXCL8
38 common cold 31.1 IL6 IL4 IL1B IFNA2 CXCL8 ACE2
39 liver disease 31.1 IL6 IL1B IFNA2 F3 CXCL8
40 atrioventricular block 31.1 TNNI3 NPPB ACE
41 acute myocardial infarction 31.1 TNNI3 NPPB IL6 F3 ACE
42 urinary tract infection 31.1 TLR4 ACE
43 allergic disease 31.0 TLR4 IL6 IL4 IL1B CXCL10
44 acne 31.0 IL6 IL1B IFNA2 CXCL8
45 cardiac tamponade 31.0 TNNI3 NPPB F3 ACE
46 end stage renal disease 31.0 NPPB IL6 IL1B CCL2 ACE
47 polyneuropathy 31.0 IL6 IL1B IFNA2 ACE
48 pulmonary edema 31.0 TNNI3 NPPB IL1B CXCL8 ACE
49 neuromyelitis optica 31.0 IL6 IL4 IL1B CXCL10
50 neutropenia 31.0 TLR4 IL6 IL4 IL1B IFNA2 CXCL8

Graphical network of the top 20 diseases related to Covid-19:



Diseases related to Covid-19
Sources

Symptoms & Phenotypes for Covid-19

About this section

MGI Mouse Phenotypes related to Covid-19:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.29 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
2 hematopoietic system MP:0005397 10.28 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
3 growth/size/body region MP:0005378 10.27 ACE ACE2 ADAM17 DPP4 EGFR F3
4 immune system MP:0005387 10.27 ACE ACE2 ADAM17 CCL2 CXCL10 DPP4
5 homeostasis/metabolism MP:0005376 10.25 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
6 mortality/aging MP:0010768 10.2 ACE ACE2 ADAM17 CXCL10 DPP4 EGFR
7 muscle MP:0005369 9.86 ACE2 ADAM17 EGFR F3 IL6 NRP1
8 neoplasm MP:0002006 9.81 ACE EGFR F3 IFNB1 IL1B IL6
9 respiratory system MP:0005388 9.7 ACE2 ADAM17 DPP4 EGFR F3 IL2RA
10 vision/eye MP:0005391 9.32 ACE ACE2 ADAM17 EGFR F3 IL2RA
Sources

Drugs & Therapeutics for Covid-19

About this section

Drugs for Covid-19 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 831)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ledipasvir Approved Phase 4 1256388-51-8 67505836
2 Bentonite Approved Phase 4
3
Nitazoxanide Approved, Investigational, Vet_approved Phase 4 55981-09-4 41684
4
Zinc Approved, Investigational Phase 4 7440-66-6 32051
5
Ivermectin Approved, Investigational, Vet_approved Phase 4 70288-86-7 6474909
6
Clarithromycin Approved Phase 4 81103-11-9 84029
7
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
8
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
9
Ibuprofen Approved Phase 4 15687-27-1 3672
10
Rivaroxaban Approved Phase 4 366789-02-8
11
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
12
Protein C Approved Phase 4
13
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
14
Ofloxacin Approved Phase 4 82419-36-1 4583
15
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
16
Piperacillin Approved Phase 4 66258-76-2 43672
17
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
18
Tazobactam Approved Phase 4 89786-04-9 123630
19
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
20
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
21
Ticagrelor Approved Phase 4 274693-27-5 9871419
22
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
23
Fondaparinux Approved, Investigational Phase 4 104993-28-4
24
Ceftriaxone Approved Phase 4 73384-59-5 5479530 5361919
25
Zinc sulfate Approved, Investigational Phase 4 7733-02-0
26
Simvastatin Approved Phase 4 79902-63-9 54454
27
Nintedanib Approved Phase 4 656247-17-5 56843413
28
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
29
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
30
Cefditoren Approved, Investigational Phase 4 104145-95-1, 117467-28-4 9571074 9870843
31
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
32
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
33
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
34 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
35
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
36
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
37
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
38
BCG vaccine Approved, Investigational Phase 4
39
Tenecteplase Approved Phase 4 191588-94-0
40
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
41
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
42
Iron Approved Phase 4 7439-89-6 23925 29936
43
Povidone-iodine Approved Phase 4 25655-41-8
44
Coal tar Approved Phase 4 8007-45-2
45
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
46
Dalteparin Approved Phase 4 9005-49-6
47
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
48
Iodine Approved, Investigational Phase 4 7553-56-2 807
49
Povidone Approved Phase 4 9003-39-8 131751496
50
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865

Interventional clinical trials:

(show top 50) (show all 4401)
# Name Status NCT ID Phase Drugs
1 Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease: a Randomised Controlled Trial Completed NCT04405999 Phase 4 Bromhexine Hydrochloride
2 An Open Clinical Trial to Evaluate Danoprevir Sodium Tablets Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04345276 Phase 4 Danoprevir+Ritonavir
3 An Open Clinical Trial to Evaluate Ganovo（Danoprevir ） Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection Completed NCT04291729 Phase 4 Ganovo+ritonavir+/-Interferon nebulization
4 TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience Completed NCT04730323 Phase 4 Tocilizumab
5 Efficacy of Adding Sofosbuvir/Ledipasvir Combination, or Nitazoxanide to the Standard of Care in Treatment of COVID-19: A Randomized Controlled Trial Completed NCT04498936 Phase 4 Sofosbuvir and Ledipasvir;Nitazoxanide
6 Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts Completed NCT04652648 Phase 4 Hydroxychloroquine
7 Ivermectin Role in Severe Covid-19 Treatment; a Double-blinded, Randomized Clinical Trial Completed NCT04746365 Phase 4 ivermectin;hydroxychloroquine;Placebo
8 Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients Completed NCT04739410 Phase 4 Ivermectin
9 Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Ambulatory Patients With COVID-19 Being at Risk of Serious Complications Completed NCT04331600 Phase 4 Chloroquine phosphate
10 Telmisartan for Treatment of COVID-19 Patients: an Open Label Randomized Trial Completed NCT04355936 Phase 4 Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
11 A Randomized Study Evaluating the Safety and Efficacy of Hydroxychloroquine and Zinc in Combination With Either Azithromycin or Doxycycline for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04370782 Phase 4 Hydroxychloroquine;Azithromycin;Zinc Sulfate;Doxycycline
12 A Randomized, Placebo-Controlled Study Evaluating the Efficacy of Zinc for the Treatment of COVID-19 in the Outpatient Setting Completed NCT04621461 Phase 4 Placebo
13 Efficacy of Fuzheng Huayu Tablets for Treating Pulmonary Inflammation in Patients With COVID-19: A Case-Control Study Completed NCT04645407 Phase 4 Fuzheng Huayu tablet
14 The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19 Completed NCT04479202 Phase 4 Berberine;Montmorrillonite
15 A Randomized Clinical Trial for Enhanced Trained Immune Responses Through Bacillus Calmette-Guérin Vaccination to Prevent Infections by COVID-19: The ACTIVATE II Trial Recruiting NCT04414267 Phase 4
16 The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19 Recruiting NCT04468139 Phase 4 Quercetin;Zinc;Vitamin C
17 Randomized Open Label Study of Standard of Care Plus an Angiotensin II Receptor Blocker Compared to Standard of Care Alone to Minimize the Progression to Respiratory Failure in SARS-CoV-2 Infection Recruiting NCT04340557 Phase 4 Losartan
18 A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection Recruiting NCT04705831 Phase 4 Ruconest
19 A Randomized Double-blinded Placebo-controlled Outpatient Clinical Trial in High Risk Population Confirmed COVID-19 Patients Using Ivermectin and Doxycycline to Prevent COVID-19 Illness-related Hospitalization (COVIVER-OUT PLUS) Recruiting NCT04729140 Phase 4 Ivermectin Tablets;Doxycycline Tablets;Placebo
20 Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19. Multicenter, Randomized, Double-blind, Placebo-controlled Trial (CARR-COV-02) Recruiting NCT04521322 Phase 4 Iota-Carrageenan
21 Fluoxetine to Reduce Intubation and Death After COVID19 Infection Recruiting NCT04377308 Phase 4 Fluoxetine
22 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R) Recruiting NCT04390464 Phase 4 Ravulizumab;Baricitinib
23 Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease Recruiting NCT04394117 Phase 4 Angiotensin Receptor Blockers
24 BCG Vaccine to Reduce Unplanned Absenteeism Due to Illness of Health Care Workers During the COVID-19 Pandemic. A Multi-center Randomised Controlled Trial (BCG-COVID-RCT) Recruiting NCT04641858 Phase 4
25 Effect of Dexamethasone in Patients With ARDS and COVID-19 - Prospective, Multi-centre, Open-label, Parallel-group, Randomized Controlled Trial (REMED Trial) Recruiting NCT04663555 Phase 4 Dexamethasone
26 The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Recruiting NCT04377750 Phase 4 Tocilizumab
27 Vitamin D Supplementation and Covid-19: a Randomised, Double- Blind, Controlled Study Recruiting NCT04636086 Phase 4 Cholecalciferol
28 Efficacy of Palmitoylethanolamide, in add-on to Standard Therapy, on Inflammatory Markers of Patients With Interstitial Pneumonia Due to COVID-19. A Pilot Controlled, Randomized, Open Lable Clinical Study Recruiting NCT04568876 Phase 4
29 Efficacy of Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19 Recruiting NCT04726098 Phase 4 Dexamethasone high dose;Dexamethasone low dose
30 Effects of Higher Dose and Lower Dose of Dexamethasone for Hospitalized Patients With COVID-19 Recruiting NCT04707534 Phase 4 Dexamethasone
31 Efficacy and Safety Study to Evaluate the Use of Nebulized Heparin in Patients With Severe Acute Respiratory Syndrome Covid-19 (SARS-CoV-2) Recruiting NCT04530578 Phase 4 Heparin sodium;Enoxaparin
32 Timing of Corticosteroids in COVID-19 Recruiting NCT04530409 Phase 4 Early-Dexamethasone;Late-Dexamethasone
33 A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic Strategies in Hospitalized Adults With COVID-19 Recruiting NCT04505774 Phase 4 theraputic heparin;prophylactic heparin
34 Open, Controlled, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Cyclosporine Plus Standard Treatment vs Standard Treatment Only in Hospitalized Patients With COVID-19 Infection Recruiting NCT04392531 Phase 4 Cyclosporine;Standard treatment
35 COVID-19-associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults With COVID-19 Recruiting NCT04360824 Phase 4 Intermediate dose thromboprophylaxis;Standard of Care thromboprophylaxis
36 Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19: A Cluster Based Randomized Selection Trial (IMPROVE-COVID) Recruiting NCT04367831 Phase 4 Enoxaparin Prophylactic Dose;Heparin Infusion;Heparin SC;Enoxaparin/Lovenox Intermediate Dose
37 COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement Recruiting NCT04369794 Phase 4
38 Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia Recruiting NCT04355026 Phase 4 Bromhexine Oral Tablet and/or hydroxychloroquine tablet
39 A Randomized, Parallel-group Treatment, Quadruple Masked, Two-arm Study, to Assess the Effectiveness of Cod Liver Oil Compared to Placebo in the Prevention of Covid-19 and Airway Infections in Healthy Adults Recruiting NCT04609423 Phase 4
40 Estudio Destinado a Valorar la Utilidad de Vitamina D Sobre Morbilidad y Mortalidad de la infección Por Virus SARS-COV-2 (COVID-19) en el Hospital Universitario Central de Asturias Recruiting NCT04552951 Phase 4 Cholecalciferol
41 Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia Recruiting NCT02735707 Phase 4 Fixed-duration Hydrocortisone;Shock-dependent hydrocortisone;Ceftriaxone;Moxifloxacin or Levofloxacin;Piperacillin-tazobactam;Ceftaroline;Amoxicillin-clavulanate;Macrolide administered for 3-5 days;Macrolide administered for up to 14 days;Five-days oseltamivir;Ten-days oseltamivir;Lopinavir/ritonavir;Hydroxychloroquine;Hydroxychloroquine + lopinavir/ritonavir;Interferon-β1a;Anakinra;Fixed-duration higher dose Hydrocortisone;Tocilizumab;Sarilumab;Vitamin C;Therapeutic anticoagulation;Simvastatin;Eritoran;Apremilast;Aspirin;Clopidogrel;Prasugrel;Ticagrelor
42 Comparison of Normal Saline, Hydrogen Peroxide, Chlorhexidine and Povidone-Iodine Mouth Rinses in COVID-19 Patients Recruiting NCT04603794 Phase 4 0.5% Povidone Iodine;0.12% Chlorhexidine Gluconate Mouth Rinse;1% Hydrogen Peroxide;0.9% Normal Saline
43 D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia Recruiting NCT04584580 Phase 4 low-molecular-weight heparin
44 Open-label, Randomized Trial of the Safety and Efficacy of Doxycycline and Rivaroxaban Therapy Versus National Standard Therapy in Ambulatory Patients With Mild Symptomatic COVID-19 Recruiting NCT04715295 Phase 4 Doxycycline Tablets;Rivaroxaban 15Mg Tab
45 Prospective, Non-controlled Pilot Study to Evaluate the Efficacy and Safety of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia Recruiting NCT04709172 Phase 4 Cefditoren pivoxil 400mg
46 Anticoagulation in Patients Suffering From COVID-19 Disease-The Anti-Co Trial Recruiting NCT04445935 Phase 4 Bivalirudin Injection;Standard treatment
47 A Multicenter, Randomized-Controlled Trial to Evaluate the Efficacy and Safety of Antithrombotic Therapy for Prevention of Arterial and Venous Thrombotic Complications in Critically-Ill COVID-19 Patients Recruiting NCT04409834 Phase 4 Unfractionated Heparin IV;Enoxaparin 1 mg/kg;Clopidogrel;Unfractionated heparin SC;Enoxaparin 40 Mg/0.4 mL Injectable Solution
48 FREEDOM COVID Anticoagulation Strategy Randomized Trial Recruiting NCT04512079 Phase 4 Enoxaparin;Apixaban
49 The Role of Vitamin D in Mitigating COVID-19 Infection Severity: Focusing on Reducing Health Disparities in South Carolina Recruiting NCT04482673 Phase 4 Daily Vitamin D3;Daily placebo;Bolus vitamin D3;Bolus placebo
50 Pragmatic, Double-blind, Placebo-controlled Randomized Clinical Trial, Evaluating Hydroxychloroquine for Prevention of Hospitalization and Respiratory Complications in Non-hospitalized Patients With Confirmed or Probable COVID-19 Recruiting NCT04466540 Phase 4 Hydroxychloroquine;Placebo

Search NIH Clinical Center for Covid-19

Sources

Genetic Tests for Covid-19

About this section

Genetic tests related to Covid-19:

# Genetic test Affiliating Genes
1 Covid-19 29
Sources

Anatomical Context for Covid-19

About this section

MalaCards organs/tissues related to Covid-19:

40
Kidney, Heart, Liver, Breast, Skin, Eye, Endothelial
Sources

Publications for Covid-19

About this section

Articles related to Covid-19:

(show top 50) (show all 30002)
# Title Authors PMID Year
1
Learning From the Past to Guide the Future: HIV and COVID-19. 42 61
33534245 2021
2
COVID-19 Pandemic: Clinical Nurse Specialist Practice Supporting Preparedness in the Spheres of Impact. 42
33534250 2021
3
Guidelines and best practice recommendations on reproductive health services provision amid COVID-19 pandemic: scoping review. 42
33536001 2021
4
SARS-CoV-2 genomic characterization and clinical manifestation of the COVID-19 outbreak in Uruguay. 61
33306459 2021
5
Disparities in case frequency and mortality of coronavirus disease 2019 (COVID-19) among various states in the United States. 61
33138653 2021
6
External validation of a clinical risk score to predict hospital admission and in-hospital mortality in COVID-19 patients. 61
32997542 2021
7
Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. 61
33491498 2021
8
Is NHS Test and Trace exacerbating COVID-19 inequalities? 61
33285140 2021
9
Age and frailty in COVID-19 vaccine development. 61
33220853 2021
10
COVID-19-associated cytokine storm syndrome and diagnostic principles: an old and new Issue. 61
33522893 2021
11
Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients. 61
33345622 2021
12
Protecting women: new domestic violence countermeasures for COVID-19 in Japan. 61
33533321 2021
13
Evaluation of a comprehensive pre-procedural screening protocol for COVID-19 in times of a high SARS CoV-2 prevalence: a prospective cross-sectional study. 61
33583292 2021
14
COVID-19 pandemic: a catalyst for transformation of a summer online research program. 61
33567998 2021
15
Applications of the High Impact Practices in Family Planning during COVID-19. 61
33599196 2021
16
Psychological problems in general population during covid-19 pandemic in Pakistan: role of cognitive emotion regulation. 61
33307858 2021
17
Admission hyperglycaemia as a predictor of mortality in patients hospitalized with COVID-19 regardless of diabetes status: data from the Spanish SEMI-COVID-19 Registry. 61
33063540 2021
18
Hematologic autoimmune disorders in the course of COVID-19: a systematic review of reported cases. 61
33594951 2021
19
Evaluation of the susceptibility and fatality of lung cancer patients towards the COVID-19 infection: A systemic approach through analyzing the ACE2, CXCL10 and their co-expressed genes. 61
33585826 2021
20
Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT). 61
32808808 2021
21
COVID-19 epidemic in Libya. 61
33407008 2021
22
COVID-19 evolution during the pandemic - Implications of new SARS-CoV-2 variants on disease control and public health policies. 61
33494661 2021
23
ECONOMIC CRISES AS A MOTIVE FOR CHANGE IN HEALTH CARE SYSTEMS - A HISTORICAL PERSPECTIVE WITH REFERENCE TO THE COVID-19 PANDEMIC. 61
33535767 2021
24
Understanding the Slow COVID-19 Trajectory of Cambodia. 61
33521738 2021
25
The effects of the COVID-19 pandemic on food losses in the agricultural value chains in Africa: The Nigerian case study. 61
33564750 2021
26
A rapid review of the use of face mask in preventing the spread of COVID-19. 61
33313575 2021
27
Nursing and precision predictive analytics monitoring in the acute and intensive care setting: An emerging role for responding to COVID-19 and beyond. 61
33426534 2021
28
COVID-19, stock market and sectoral contagion in US: a time-frequency analysis. 61
33583992 2021
29
COVID-19 interferes in the disclosure of the first Brazilian GIAHS site. 61
33053142 2021
30
Public attention about COVID-19 on social media: An investigation based on data mining and text analysis. 61
33536695 2021
31
Analyzing National Responses to COVID-19 Pandemic using STPA. 61
33558791 2021
32
The impact of COVID-19 on pediatric vaccination rates in Alabama. 61
33564619 2021
33
How did socio-demographic status and personal attributes influence compliance to COVID-19 preventive behaviours during the early outbreak in Japan? Lessons for pandemic management. 61
33526954 2021
34
The role of ideological attitudes in responses to COVID-19 threat and government restrictions in Australia. 61
33583988 2021
35
Influence of grit on lifestyle factors during the COVID-19 pandemic in a sample of adults in the United States. 61
33531728 2021
36
Perceived susceptibility to COVID-19 infection and narcissistic traits. 61
33558779 2021
37
Point of care detection of COVID-19: Advancement in biosensing and diagnostic methods. 61
33551668 2021
38
COVID-19, triage decisions, and indirect ethics: A model for the re-evaluation of triage guidelines. 61
33585667 2021
39
A baseline review of the ability of hospitals in Kenya to provide emergency and critical care services for COVID-19 patients. 61
33495726 2021
40
Associations between meteorology and COVID-19 in early studies: Inconsistencies, uncertainties, and recommendations. 61
33585669 2021
41
Impact of climatic, demographic and disease control factors on the transmission dynamics of COVID-19 in large cities worldwide. 61
33558848 2021
42
Increased incidence of chalazion associated with face mask wear during the COVID-19 pandemic. 61
33585724 2021
43
Moral decision-making and support for safety procedures amid the COVID-19 pandemic. 61
33551530 2021
44
COVID-19: Public health issues and ethical dilemmas. 61
33553555 2021
45
Influence of population density, temperature, and absolute humidity on spread and decay durations of COVID-19: A comparative study of scenarios in China, England, Germany, and Japan. 61
33344745 2021
46
Sitagliptin: a potential drug for the treatment of COVID-19? 61
33151168 2021
47
Legislation advancement of one health in China in the context of the COVID-19 pandemic: From the perspective of the wild animal conservation law. 61
33335968 2021
48
Assessing the impact of non-pharmaceutical interventions on the transmissibility and severity of COVID-19 during the first five months in the Western Pacific Region. 61
33506086 2021
49
COVID-19 national lockdown in morocco: Impacts on air quality and public health. 61
33263072 2021
50
The COVID-19 pandemic: A time for veterinary leadership in one health. 61
33304981 2021
Sources

Variations for Covid-19

About this section
Sources

Expression for Covid-19

About this section
Search GEO for disease gene expression data for Covid-19.
Sources

Pathways for Covid-19

About this section

Pathways related to Covid-19 according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.09 TLR4 IL6 IL4 IL2RA IL1B IFNB1
2
ERK Signaling 63
Show member pathways
 13.88 NRP1 IL6 IL4 IL2RA IL1B EGFR
3
PEDF Induced Signaling 63
Show member pathways
 13.72 TLR4 IL6 IL4 IL2RA IL1B IFNB1
4
Viral mRNA Translation 65
Show member pathways
 13.72 TMPRSS2 TLR4 NRP1 IL6 IL1B IFNB1
5
TGF-Beta Pathway 63
Show member pathways
 13.6 IL6 IL4 IL2RA IL1B IFNB1 IFNA2
6
Akt Signaling 63
Show member pathways
 13.45 TLR4 IL6 IL4 IL2RA IL1B EGFR
7
PAK Pathway 63
Show member pathways
 13.34 NRP1 IL6 IL4 IL2RA IL1B EGFR
8
Cytokine Signaling in Immune system 65
Show member pathways
 13.33 IL6 IL4 IL2RA IL1B IFNB1 IFNA2
9
p70S6K Signaling 63
Show member pathways
 13.11 NRP1 IL6 IL4 IL2RA EGFR CCL2
10
PI3K-Akt signaling pathway 36
Show member pathways
 13.04 TLR4 IL6 IL4 IL2RA IFNB1 IFNA2
11
Toll-like Receptor Signaling Pathway 36 1
Show member pathways
 12.99 TLR4 IL6 IL1B IFNB1 IFNA2 EGFR
12
Human cytomegalovirus infection 36
Show member pathways
 12.97 TLR4 IL6 IL1B IFNB1 IFNA2 EGFR
13
Allograft rejection 36 1
Show member pathways
 12.91 IL6 IL4 IL2RA IL1B IFNA2 CXCL8
14
Pathways in cancer 36
12.9 IL6 IL4 IL2RA IFNA2 EGFR CXCL8
15
Herpes simplex virus 1 infection 36
12.83 IL6 IL1B IFNB1 IFNA2 CCL2
16
Toll-Like receptor Signaling Pathways 64
Show member pathways
 12.73 TLR4 IL6 IL1B IFNB1 IFNA2 F3
17
T cell receptor signaling pathway 36
Show member pathways
 12.66 TLR4 IL6 IL4 IL1B EGFR
18
Th17 cell differentiation 36
Show member pathways
 12.65 TLR4 IL6 IL4 IL2RA IL1B
19
NF-kappaB Signaling 4
12.63 IL4 IL2RA IL1B CXCL10 CCL2
20
Cytosolic sensors of pathogen-associated DNA 65
Show member pathways
 12.61 IL6 IL1B IFNB1 IFNA2 CXCL10
21
JAK-STAT signaling pathway 36
Show member pathways
 12.49 IL6 IL4 IL2RA IFNB1 IFNA2 EGFR
22
Shigellosis 36
12.47 TLR4 IL1B IFNB1 EGFR CXCL8
23
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.4 IL6 IL2RA CXCL8 CXCL10 CCL2
24
IL-17 Family Signaling Pathways 64
Show member pathways
 12.4 IL6 IL4 IL1B CXCL8 CXCL10 CCL2
25
Folate Metabolism 1
Show member pathways
 12.37 IL6 IL4 IL1B CCL2
26
Measles 36
Show member pathways
 12.36 TMPRSS2 TLR4 IL6 IL2RA IL1B IFNB1
27
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.31 TLR4 IL6 IFNB1 CXCL8
28
Tuberculosis 36
12.3 TLR4 IL6 IL1B IFNB1 IFNA2
29
Necroptosis 36
Show member pathways
 12.26 TLR4 IL1B IFNB1 IFNA2
30
NOD-like receptor signaling pathway 36
12.17 TLR4 IL6 IL1B IFNB1 IFNA2 CXCL8
31
Yersinia infection 36
12.12 TLR4 IL6 IL1B IFNB1 CXCL8 CCL2
32
MAPK Pathway 70
Show member pathways
 12.09 TLR4 IL2RA IL1B EGFR
33
Bacterial infections in CF airways 23
Show member pathways
 12.08 TLR4 IL6 IL4 IL1B IFNB1 CXCL8
34
Interleukin-4 and 13 signaling 65
12.07 IL6 IL4 IL1B CXCL8 CCL2
35
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.06 IL6 IL4 IL2RA IFNA2
36
TNF signaling pathway 36
12.05 IL6 IL1B IFNB1 CXCL10 CCL2
37
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.02 NRP1 IL6 IL4 IL2RA IL1B IFNB1
38
Senescence and Autophagy in Cancer 1
12.01 IL6 IL1B IFNB1 CXCL8
39
Amoebiasis 36
11.99 TLR4 IL6 IL1B CXCL8
40
AGE-RAGE signaling pathway in diabetic complications 36
11.99 IL6 IL1B F3 CXCL8 CCL2
41
Hematopoietic cell lineage 36
11.97 IL6 IL4 IL2RA IL1B
42
Th17 Differentiation Pathway 64
Show member pathways
 11.93 TLR4 IL6 IL4 IL1B
43
Rheumatoid arthritis 36
11.92 TLR4 IL6 IL1B CXCL8 CCL2
44
Pertussis 36
11.84 TLR4 IL6 IL1B CXCL8
45
Glucocorticoid receptor regulatory network 1
11.83 IL6 IL4 CXCL8
46
Innate Lymphoid Cell Differentiation Pathways 64
11.82 IL4 IL2RA IL1B
47
Dendritic Cells Developmental Lineage Pathway 64
11.8 NRP1 IL6 IL1B IFNB1 IFNA2
48
Th1 Differentiation Pathway 64
Show member pathways
 11.79 TLR4 IL6 IL1B
49
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.79 IL4 IL2RA CXCL8
50
IgA-Producing B Cells in the Intestine 64
11.77 TLR4 IL6 IL4 IL2RA
Sources

GO Terms for Covid-19

About this section

Cellular components related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 NRP1 NPPB IL6 IL4 IL1B IFNB1
2 cell surface GO:0009986 9.76 TLR4 NRP1 IL2RA F3 EGFR DPP4
3 membrane raft GO:0045121 9.56 EGFR DPP4 ADAM17 ACE2
4 extracellular region GO:0005576 9.53 TMPRSS2 NRP1 NPPB IL6 IL4 IL1B

Biological processes related to Covid-19 according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.28 TLR4 NRP1 IL6 IL4 IL1B EGFR
2 positive regulation of gene expression GO:0010628 10.04 TLR4 IL6 IL4 IL1B F3 CXCL8
3 positive regulation of cell proliferation GO:0008284 10.02 IL6 IL4 IL1B EGFR DPP4 CXCL10
4 cell-cell signaling GO:0007267 9.97 NRP1 IL1B IFNA2 CXCL10
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 TLR4 NRP1 EGFR CCL2
6 defense response to virus GO:0051607 9.94 IL6 IFNB1 IFNA2 CXCL10
7 response to lipopolysaccharide GO:0032496 9.92 TLR4 IL1B CXCL10 ADAM17
8 defense response GO:0006952 9.91 IFNB1 IFNA2 CXCL8 CXCL10
9 cellular response to mechanical stimulus GO:0071260 9.85 TLR4 IL1B EGFR
10 neutrophil chemotaxis GO:0030593 9.85 CXCL8 CXCL10 CCL2
11 positive regulation of cell migration GO:0030335 9.85 IL4 IL1B F3 EGFR CXCL10 ADAM17
12 regulation of insulin secretion GO:0050796 9.84 IL6 IL1B DPP4
13 viral entry into host cell GO:0046718 9.84 NRP1 EGFR DPP4 ACE2
14 chemokine-mediated signaling pathway GO:0070098 9.83 CXCL8 CXCL10 CCL2
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 IL6 IL4 IFNA2
16 B cell differentiation GO:0030183 9.83 IL4 IFNB1 IFNA2 ADAM17
17 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.82 TLR4 IL1B EGFR
18 positive regulation of T cell proliferation GO:0042102 9.81 IL6 IL4 IL2RA IL1B
19 cellular response to lipopolysaccharide GO:0071222 9.8 TLR4 IL6 IL1B CXCL8 CXCL10 CCL2
20 cell surface receptor signaling pathway GO:0007166 9.8 NPPB IL2RA IFNB1 IFNA2 EGFR CXCL10
21 positive regulation of chemokine production GO:0032722 9.77 TLR4 IL6 ADAM17
22 positive regulation of interleukin-10 production GO:0032733 9.77 TLR4 IL6 IL4
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TLR4 IL1B CCL2
24 positive regulation of interleukin-8 production GO:0032757 9.76 TLR4 IL6 IL1B F3
25 immune response GO:0006955 9.76 TLR4 IL6 IL4 IL2RA IL1B CXCL8
26 positive regulation of phosphorylation GO:0042327 9.75 NRP1 IFNA2 EGFR
27 humoral immune response GO:0006959 9.73 IL6 IFNB1 IFNA2 CCL2
28 regulation of blood vessel diameter GO:0097746 9.72 NPPB ACE2 ACE
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.68 TLR4 IL4
30 positive regulation of leukocyte chemotaxis GO:0002690 9.67 IL6 CXCL10 ADAM17
31 negative regulation of T cell differentiation GO:0045581 9.64 IFNB1 IFNA2
32 vascular endothelial growth factor production GO:0010573 9.63 IL6 IL1B
33 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.63 ACE2 ACE
34 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.61 IFNB1 IFNA2
35 neutrophil mediated immunity GO:0002446 9.58 IL6 ADAM17 ACE
36 negative regulation of gap junction assembly GO:1903597 9.56 IL1B ACE
37 inflammatory response GO:0006954 9.56 TLR4 IL6 IL2RA IL1B IFNA2 CXCL8
38 cytokine-mediated signaling pathway GO:0019221 9.32 IL6 IL4 IL2RA IL1B IFNB1 IFNA2

Molecular functions related to Covid-19 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.26 TNNI3 TMPRSS2 TLR4 NRP1 NPPB IL6
2 virus receptor activity GO:0001618 9.61 EGFR DPP4 ACE2
3 chemokine activity GO:0008009 9.54 CXCL8 CXCL10 CCL2
4 signaling receptor binding GO:0005102 9.43 TLR4 NPPB EGFR DPP4 CXCL10 CCL2
5 interleukin-6 receptor binding GO:0005138 9.4 IL6 ADAM17
6 cytokine receptor binding GO:0005126 9.33 IL4 IFNB1 IFNA2
7 peptidyl-dipeptidase activity GO:0008241 9.32 ACE2 ACE
8 cytokine activity GO:0005125 9.23 IL6 IL4 IL1B IFNB1 IFNA2 CXCL8
Sources

Sources for Covid-19

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....